Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1985 3
1986 1
1987 2
1989 1
1990 6
1991 1
1992 3
1994 2
1995 2
1997 5
1998 1
1999 4
2000 7
2001 2
2002 6
2003 2
2004 7
2006 2
2007 2
2008 4
2009 1
2010 2
2011 3
2012 1
2013 2
2014 2
2015 3
2016 5
2017 6
2018 4
2019 4
2020 9
2021 9
2022 13
2023 10
2024 11
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Cheung GW, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia PJ. Ghorashian S, et al. Among authors: kramer am. Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2. Nat Med. 2019. PMID: 31477906 Clinical Trial.
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Srinagesh H, Jackson C, Shiraz P, Jeyakumar N, Hamilton M, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai A, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston L, Kennedy V, Liedtke M, Lowsky R, Mikkilineni L, Negrin R, Rezvani A, Sidana S, Shizuru J, Smith M, Weng WK, Feldman S, Frank MJ, Lee Z, Tagliaferri M, Marcondes AM, Miklos D, Mackall C, Muffly L. Srinagesh H, et al. Among authors: kramer am. Blood. 2024 Oct 17;144(16):1689-1698. doi: 10.1182/blood.2024024952. Blood. 2024. PMID: 38968138 Clinical Trial.
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, Oak JS, Younes SF, Natkunam Y, Hamilton MP, Su YJ, Agarwal N, Chinnasamy H, Egeler E, Mavroukakis S, Feldman SA, Sahaf B, Mackall CL, Muffly L, Miklos DB; CARdinal-22 Investigator group. Frank MJ, et al. Among authors: kramer am. Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9. Lancet. 2024. PMID: 38996463 Free PMC article. Clinical Trial.
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, Srinagesh H, Shiraz P, Agarwal N, Hamilton M, Erickson C, Jacobs A, Moon J, Baggott C, Arai S, Bharadwaj S, Johnston LJ, Liedtke M, Lowsky R, Meyer E, Negrin R, Rezvani A, Shizuru J, Sidana S, Egeler E, Mavroukakis S, Tunuguntla R, Gkitsas-Long N, Retherford A, Brown AK, Gramstrap-Petersen AL, Ibañez RM, Feldman SA, Miklos DB, Mackall CL, Davis KL, Frank M, Ramakrishna S, Muffly L. Schultz LM, et al. Among authors: kramer am. Leukemia. 2024 May;38(5):963-968. doi: 10.1038/s41375-024-02220-y. Epub 2024 Mar 15. Leukemia. 2024. PMID: 38491306 Clinical Trial.
Refractive Error Change and Overminus Lens Therapy for Childhood Intermittent Exotropia.
Writing Committee for the Pediatric Eye Disease Investigator Group; Pediatric Eye Disease Investigator Group; Chen AM, Erzurum SA, Chandler DL, Hercinovic A, Wu R, Vricella M, Waters AL, Ticho BH, Erickson JW, Han S, McDowell PS, Li Z, Kraker RT, Holmes JM, Cotter SA. Writing Committee for the Pediatric Eye Disease Investigator Group, et al. JAMA Ophthalmol. 2024 May 1;142(5):417-428. doi: 10.1001/jamaophthalmol.2024.0276. JAMA Ophthalmol. 2024. PMID: 38536764 Free PMC article. Clinical Trial.
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
Su YJ, Kramer AM, Hamilton MP, Agarwal N, Srinagesh HK, Baird JH, Sahaf B, Kuo A, Ehlinger ZJ, Desai MH, Rietberg SP, Tunuguntla R, Patel S, Chinnasamy H, Gkitsas-Long N, Klysz DD, Brown AK, Bharadwaj S, Dahiya S, Smith M, Muffly L, Mackall CL, Good Z, Feldman SA, Miklos DB, Frank MJ. Su YJ, et al. Among authors: kramer am. Cancer Discov. 2025 Apr 2;15(4):733-747. doi: 10.1158/2159-8290.CD-24-1071. Cancer Discov. 2025. PMID: 39775812
Global Patterns of Zoonotic Disease in Mammals.
Han BA, Kramer AM, Drake JM. Han BA, et al. Among authors: kramer am. Trends Parasitol. 2016 Jul;32(7):565-577. doi: 10.1016/j.pt.2016.04.007. Epub 2016 Jun 14. Trends Parasitol. 2016. PMID: 27316904 Free PMC article. Review.
Land reversion and zoonotic spillover risk.
Vinson JE, Gottdenker NL, Chaves LF, Kaul RB, Kramer AM, Drake JM, Hall RJ. Vinson JE, et al. Among authors: kramer am. R Soc Open Sci. 2022 Jun 8;9(6):220582. doi: 10.1098/rsos.220582. eCollection 2022 Jun. R Soc Open Sci. 2022. PMID: 35706674 Free PMC article.
Comparison of Methods for Measuring Cyclodeviation.
Liebermann L, Hatt SR, Leske DA, Klaehn LD, Kramer AM, Holmes JM. Liebermann L, et al. Among authors: kramer am. Am J Ophthalmol. 2021 Apr;224:332-342. doi: 10.1016/j.ajo.2020.11.005. Epub 2020 Nov 27. Am J Ophthalmol. 2021. PMID: 33253661 Free PMC article.
140 results